Adaptive Radiative Thermal Management Using Transparent, Flexible Ag Nanowire Networks.

Effective heat management is critical for improving energy efficiency and minimizing environmental impact. Passive radiative heat management systems rely on specific materials and design configurations to naturally modulate temperature, enhance system reliability, and decrease operational costs by modulating infrared light. However, their static nature proves insufficient in dynamic settings experiencing significant temperature fluctuations.

Development of Antibacterial Hydrogels Based on Biopolymer Aloe Vera/Gelatin/Sodium Alginate Composited With SM-AgNPs Loaded Curcumin-Nanoliposomes.

To address the rising prevalence of bacterial infections and the need for innovative therapeutic solutions, this study has developed a novel antibacterial hydrogel composite composed of Aloe vera, gelatin, sodium alginate, and Sterculia monosperma-silver nanoparticles (SM-AgNPs) loaded curcumin-nanoliposomes (NLPs). The aloe vera/gelatin/sodium alginate hydrogels (AGS) are prepared using different weight ratios of Aloe vera, gelatin, and sodium alginate, aiming to optimize mechanical properties and biocompatibility for biomedical applications. The incorporation of SM-AgNPs and curcumin-loaded NLPs enhanced the hydrogels' antibacterial properties.

Small-Molecule Modulators of Lipid Raft Stability and Protein-Raft Partitioning.

Development of an understanding of membrane nanodomains colloquially known as "lipid rafts" has been hindered by a lack of pharmacological tools to manipulate rafts and protein affinity for rafts. We screened 24,000 small molecules for modulators of the affinity of peripheral myelin protein 22 (PMP22) for rafts in giant plasma membrane vesicles (GPMVs). Hits were counter-screened against another raft protein, MAL, and tested for impact on raft , leading to two classes of compounds.

Safety, Pharmacokinetics, and Pharmacodynamics of a First-in-Class ClC-1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial.

NMD670 is a first-in-class inhibitor of skeletal muscle-specific chloride channel ClC-1, developed to improve muscle weakness and fatigue in neuromuscular diseases. Preclinical studies show that ClC-1 inhibition enhances muscle excitability, improving muscle contractility and strength. We describe the first-in-human, randomized, double-blind, placebo-controlled study, which evaluated the safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of NMD670 in healthy male and female subjects.